Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069940 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00069940 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute.
The verdict
NCT00069940, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given together with sargramostim in treating patients with advanced sarcoma or brain tumor.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL telomerase: 540-548 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069940
The ClinicalTrials.gov registry entry for NCT00069940 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT00069940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00069940 about?
NCT00069940 is a clinical study titled "Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill ...
What is the current status of trial NCT00069940?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00069940?
The interventions under investigation include: sargramostim (BIOLOGICAL), telomerase: 540-548 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00069940?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.